Advertisement

Endocrine

, Volume 46, Issue 3, pp 554–560 | Cite as

Coexistence of thyroglobulin antibodies and thyroid peroxidase antibodies correlates with elevated thyroid-stimulating hormone level and advanced tumor stage of papillary thyroid cancer

  • Xiaoyu Wu
  • Yu Lun
  • Han Jiang
  • Qingwei Gang
  • Shijie Xin
  • Zhiquan Duan
  • Jian Zhang
Original Article

Abstract

The correlation between thyroglobulin antibodies (TgAb) or thyroid peroxidase antibodies (TPOAb) and papillary thyroid cancer (PTC) remains controversial. This histological study aimed to explore the correlation between thyroid autoantibodies (TAb), thyroid-stimulating hormone (TSH), and PTC in patients with thyroid nodules (TN). This was a retrospective study. 2,132 non-autoimmune thyroid diseases (AITD) patients who underwent thyroidectomy were subdivided into: TgAb or TPOAb single positive (TgAb+ or TPOAb+) TN group; TgAb and TPOAb double positive or negative (TAb+ or TAb−) TN group. PTC patients showed a higher rate of TAb+ TN (10.24 vs. 4.89 %; P = 0.000) and a higher TSH level (1.83 ± 0.07 vs. 1.39 ± 0.03 mIU/L; P = 0.000) than patients with benign nodules. TAb+ TN patients showed a higher TSH level and PTC frequency than those with TAb− TN (1.91 ± 0.17 vs. 1.47 ± 0.03 mIU/L; P = 0.011) (41.35 vs. 22.08 %; P = 0.000). In PTC, TAb+ TN patients showed a higher TSH level (2.57 ± 0.35 vs. 1.79 ± 0.07 mIU/L; P = 0.032), a greater frequency of lymph node metastasis (52.73 vs. 36.51 %, P = 0.026), and a lower micro-PTC frequency (16.36 vs. 39.51 %; P = 0.001) than TAb− TN patients. PTC was correlated with TgAb+ TN (OR = 1.921, CI 1.431–2.580; P = 0.000), TPOAb+ TN (OR = 1.945, CI 1.195–3.165; P = 0.007), TAb+ TN (OR = 2.393, CI 1.635–3.501; P = 0.000), and serum TSH >1.35 mIU/L (OR = 1.742, CI 1.089–2.786; P = 0.021). Serum positive TgAb or TPOAb is an independent predictor for PTC regardless of AITD. The coexistence of TgAb and TPOAb confers a greater risk for PTC than isolated positive TgAb or TPOAb, and is correlated with elevated TSH level and advanced PTC stage.

Keywords

Thyroglobulin antibodies Thyroid peroxidase antibodies Thyroid-stimulating hormone Papillary thyroid cancer Thyroid immunity Prognosis 

Notes

Acknowledgments

We gratefully acknowledge the valuable advice and kind help from the staff in Institute of Pathology of China Medical University. We would also like to thank the staff from Department of Vascular & Thyroid Surgery of The First Hospital of China Medical University for their kind help.

Conflict of interest

The authors declare that they have no conflict of interests.

References

  1. 1.
    L. Davies, H.G. Welch, Increasing incidence of thyroid cancer in the United States, 1973–2002. JAMA 295, 2164–2167 (2006)PubMedCrossRefGoogle Scholar
  2. 2.
    H. Gharib, Fine-needle aspiration biopsy of thyroid nodules: advantages, limitations, and effect. Mayo Clin. Proc. 69, 44–49 (1994)PubMedCrossRefGoogle Scholar
  3. 3.
    C. Zafon, G. Obiols, J.A. Baena, J. Castellví, B. Dalama, J. Mesa, Preoperative thyrotropin serum concentrations gradually increase from benign thyroid nodules to papillary thyroid microcarcinomas, then to papillary thyroid cancers of larger size. J. Thyroid Res. 2012, 530721 (2012)PubMedCentralPubMedCrossRefGoogle Scholar
  4. 4.
    E. Fiore, T. Rago, M.A. Provenzale et al., Lower levels of TSH are associated with a lower risk of papillary thyroid cancer in patients with thyroid nodular disease: thyroid autonomy may play a protective role. Endocr. Relat. Cancer 16, 1251–1260 (2009)PubMedCrossRefGoogle Scholar
  5. 5.
    K. Boelaert, J. Horacek, R.L. Holder, J.C. Watkinson, M.C. Sheppard, J.A. Franklyn, Serum thyrotropin concentration as a novel predictor of malignancy in thyroid nodules investigated by fine-needle aspiration. J. Clin. Endocrinol. Metab. 91, 4295–4301 (2006)PubMedCrossRefGoogle Scholar
  6. 6.
    M.R. Haymart, S.L. Glinberg, J. Liu, R.S. Sippel, J.C. Jaume, H. Chen, Higher serum TSH in thyroid cancer patients occurs independent of age and correlates with extra thyroidal extension. Clin. Endocrinol. 71, 434–439 (2009)CrossRefGoogle Scholar
  7. 7.
    M.R. Haymart, D.J. Repplinger, G.E. Leverson et al., Higher serum thyroid stimulating hormone level in thyroid nodule patients is associated with greater risks of differentiated thyroid cancer and advanced tumor stage. J. Clin. Endocrinol. Metab. 93, 809–814 (2008)PubMedCentralPubMedCrossRefGoogle Scholar
  8. 8.
    T.G. Strieder, M.F. Prummel, J.G. Tijssen, E. Endert, W.M. Wiersinga, Risk factors for and prevalence of thyroid disorders in a cross-sectional study among healthy female relatives of patients with autoimmune thyroid disease. Clin. Endocrinol. 59, 396–401 (2003)CrossRefGoogle Scholar
  9. 9.
    Y. Lun, X. Wu, Q. Xia et al., Hashimoto’s thyroiditis as a risk factor of papillary thyroid cancer may improve cancer prognosis. Otolaryngol. Head Neck Surg. 148, 396–402 (2013)PubMedCrossRefGoogle Scholar
  10. 10.
    J.G. Hollowell, N.W. Staehling, W.D. Flanders et al., Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J. Clin. Endocrinol. Metab. 87, 489–499 (2002)PubMedCrossRefGoogle Scholar
  11. 11.
    C.A. Spencer, Clinical review: clinical utility of thyroglobulin antibody (TgAb) measurements for patients with differentiated thyroid cancers (DTC). J. Clin. Endocrinol. Metab. 96, 3615–3627 (2011)PubMedCrossRefGoogle Scholar
  12. 12.
    F. Boi, M.L. Lai, B. Marziani, L. Minerba, G. Faa, S. Mariotti, High prevalence of suspicious cytology in thyroid nodules associated with positive thyroid autoantibodies. Eur. J. Endocrinol. 153, 637–642 (2005)PubMedCrossRefGoogle Scholar
  13. 13.
    F. Boi, L. Minerba, M.L. Lai et al., Both thyroid autoimmunity and increased serum TSH are independent risk factors for malignancy in patients with thyroid nodules. J. Endocrinol. Invest. 36, 313–320 (2013)PubMedGoogle Scholar
  14. 14.
    E.S. Kim, D.J. Lim, K.H. Baek et al., Thyroglobulin antibody is associated with increased cancer risk in thyroid nodules. Thyroid 20, 885–891 (2010)PubMedCrossRefGoogle Scholar
  15. 15.
    E. Fiore, T. Rago, M. Scutari et al., Papillary thyroid cancer, although strongly associated with lymphocytic infiltration on histology, is only weakly predicted by serum thyroid auto-antibodies in patients with nodular thyroid diseases. J. Endocrinol. Invest. 32, 344–351 (2009)PubMedCrossRefGoogle Scholar
  16. 16.
    C.A. Spencer, J.G. Hollowell, M. Kazarosyan, L.E. Braverman, National Health and Nutrition Examination Survey III thyroid-stimulating hormone (TSH)–thyroperoxidase antibody relationships demonstrate that TSH upper reference limit may be skewed by occult thyroid dysfunction. J. Clin. Endocrinol. Metab. 92, 4236–4240 (2007)PubMedCrossRefGoogle Scholar
  17. 17.
    D.S. McLeod, D.S. Cooper, The incidence and prevalence of thyroid autoimmunity. Endocrine 42, 252–265 (2012)PubMedCrossRefGoogle Scholar
  18. 18.
    L.M. Coussens, Z. Werb, Inflammation and cancer. Nature 420, 860–867 (2002)PubMedCentralPubMedCrossRefGoogle Scholar
  19. 19.
    M.E. Dailey, S. Lindsay, R. Skahen, Relation of thyroid neoplasms to Hashimoto disease of the thyroid gland. AMA Arch. Surg. 70, 291–297 (1955)PubMedCrossRefGoogle Scholar
  20. 20.
    M.H. Rho, D.W. Kim, H.P. Hong et al., Diagnostic value of antithyroid peroxidase antibody for incidental autoimmune thyroiditis based on histopathologic results. Endocrine 42, 647–652 (2012)PubMedCrossRefGoogle Scholar
  21. 21.
    B. Jankovic, K.T. Le, J.M. Hershman, Clinical review: Hashimoto’s thyroiditis and papillary thyroid carcinoma: is there a correlation? J. Clin. Endocrinol. Metab. 98, 474–482 (2013)PubMedCrossRefGoogle Scholar
  22. 22.
    E. Fiore, P. Vitti, Serum TSH and risk of papillary thyroid cancer in nodular thyroid disease. J. Clin. Endocrinol. Metab. 97, 1134–1145 (2012)PubMedCrossRefGoogle Scholar
  23. 23.
    J.D. French, Z.J. Weber, D.L. Fretwell, S. Said, J.P. Klopper, B.R. Haugen, Tumor-associated lymphocytes and increased FoxP3+ regulatory T cell frequency correlate with more aggressive papillary thyroid cancer. J. Clin. Endocrinol. Metab. 95, 2325–2333 (2010)PubMedCentralPubMedCrossRefGoogle Scholar
  24. 24.
    B. Singh, A.R. Shaha, H. Trivedi, J.F. Carew, A. Poluri, J.P. Shah, Coexistent Hashimoto’s thyroiditis with papillary thyroid carcinoma: impact of presentation, management and outcome. Surgery 126, 1070–1077 (1999)PubMedCrossRefGoogle Scholar
  25. 25.
    Y.H. Yoon, H.J. Kim, J.W. Lee, J.M. Kim, B.S. Koo, The clinicopathologic differences in papillary thyroid carcinoma with or without co-existing chronic lymphocytic thyroiditis. Eur. Arch. Otorhinolaryngol. 269, 1013–1017 (2012)PubMedCrossRefGoogle Scholar
  26. 26.
    F. Basolo, L. Torregrossa, R. Giannini et al., Correlation between the BRAFV600E mutation and tumor invasiveness in papillary thyroid carcinomas smaller than 20 millimeters: analysis of 1060 cases. J. Clin. Endocrinol. Metab. 95, 4197–4205 (2010)PubMedCrossRefGoogle Scholar
  27. 27.
    F. Consorti, M. Loponte, F. Milazzo, L. Potasso, A. Antonaci, Risk of malignancy from thyroid nodular disease as an element of clinical management of patients with Hashimoto’s thyroiditis. Eur. Surg. Res. 45, 333–337 (2010)PubMedCrossRefGoogle Scholar
  28. 28.
    H.S. Kim, Y.J. Choi, J.S. Yun, Features of papillary thyroid microcarcinoma in the presence and absence of lymphocytic thyroiditis. Endocr. Pathol. 21, 149–153 (2010)PubMedCrossRefGoogle Scholar
  29. 29.
    E. Fiore, T. Rago, F. Latrofa et al., Hashimoto’s thyroiditis is associated with papillary thyroid carcinoma: role of TSH and of treatment with L-thyroxine. Endocr. Relat. Cancer 18, 429–437 (2011)PubMedCrossRefGoogle Scholar
  30. 30.
    S. Andersen, F. Iversen, S. Terpling, K.M. Pedersen, P. Gustenhoff, P. Laurberg, Iodine deficiency influences thyroid autoimmunity in old age—a comparative population-based study. Maturitas 71, 39–43 (2012)PubMedCrossRefGoogle Scholar
  31. 31.
    W. Teng, Z. Shan, X. Teng et al., Effect of iodine intake on thyroid diseases in China. N. Engl. J. Med. 354, 2783–2793 (2006)PubMedCrossRefGoogle Scholar
  32. 32.
    E.D. Williams, I. Doniach, O. Bjarnason, W. Michie, Thyroid cancer in an iodide rich area: a histopathological study. Cancer 39, 215–222 (1977)PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Xiaoyu Wu
    • 1
  • Yu Lun
    • 1
  • Han Jiang
    • 1
  • Qingwei Gang
    • 1
  • Shijie Xin
    • 1
  • Zhiquan Duan
    • 1
  • Jian Zhang
    • 1
  1. 1.Department of Vascular & Thyroid SurgeryThe First Hospital of China Medical UniversityShenyangChina

Personalised recommendations